Novartis Raises Core Profit Guidance, Books $1.9 Billion Trial Hit
Novartis raised its core profit guidance and booked a $1.9 billion hit from a drug trial setback.
Novartis raised its core profit guidance and booked a $1.9 billion hit from a drug trial setback.